CLINICAL_TRIALS
trial_result
· 2018-07-31
Clinical Trial Update: Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis [Phase 2]
Summary
Phase 2 dose-ranging study results for Macroflux PTH in postmenopausal women with osteoporosis have been completed and results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Zosano Pharma Corporation | Conditions: Osteoporosis | Phase 2 | Status: COMPLETED | Results posted: 2018-07-31